RxDoctor Payments DataLook up a doctor →

Branislav Schifferdecker, MD

Interventional Cardiology · Oklahoma City, OKNPI 1013973304

Payments from drug & device makers

$120,732in general payments, 2019–2025

Across 612 payments — averaging $197.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$50K
  • Esperion Therapeutics, Inc.$18K
  • Novartis$16K
  • Boehringer Ingelheim$13K
  • Janssen Research & Development, LLC$8K
  • Medtronic$4K
  • plus $12K from 29 others

What the payments were for

  • Speaking & faculty fees$12,37547%
  • Travel & lodging$2,88511%
  • Food & beverage$11,17342%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,732 in reported general payments places this provider in the 85th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$843,750
Medicare patients
4,464
Services billed
13,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,526$1,445,528
JardianceEmpagliflozin555$539,128
EntrestoSacubitril/Valsartan618$536,104
FarxigaDapagliflozin Propanediol424$358,511
XareltoRivaroxaban291$296,912
Repatha SureclickEvolocumab97$80,917
MultaqDronedarone Hcl59$68,831
BrilintaTicagrelor80$64,821
MounjaroTirzepatide45$63,132
Rosuvastatin Calcium2,134$43,094
Praluent PenAlirocumab40$32,756
Metoprolol Succinate2,094$29,976
Repatha SyringeEvolocumab22$25,736
VascepaIcosapent Ethyl38$24,724
ClopidogrelClopidogrel Bisulfate1,567$24,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$558$1,445,5281,526 claims
Boehringer IngelheimJardiance, Synjardy$12,789$551,114569 claims
NovartisEntresto$16,467$536,104618 claims
AstraZenecaFarxiga, Brilinta$1,129$423,332504 claims
Johnson & JohnsonXarelto$1,112$296,912291 claims
Sanofi-aventis U.S. LLCMultaq$17$68,83159 claims
Lilly USA, LLCMounjaro$1,375$63,13245 claims
Novo NordiskOzempic, Rybelsus$143$44,15739 claims
Esperion Therapeutics, Inc.Nexlizet$17,722$9,39212 claims
MerckJanuvia$59$8,95214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →